Washington Entrepreneurial Research Evaluation and Commercialization Hub

华盛顿创业研究评估和商业化中心

• 批准号: 10240679
• 负责人: RODNEY J.Y. HO
• 金额: $ 99.45万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-23 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10240679
• 关键词: Acquired Immunodeficiency Syndrome; Biological Sciences; Biomedical Research; Biotechnology; Businesses; Child; Cities; Climacteric; Collaborations; Communities; Databases; Development; Drug Interactions; Environment; Evaluation Research; Expenditure; Fostering; Foundations; Fred Hutchinson Cancer Research Center; Fruit; Funding; Gardasil; Generations; Genetic; Genetic Engineering; Goals; Governing Board; Health; Health Alliance; Health Sciences; Hepatitis B Virus; Human Papillomavirus; Individual; Industry; Infectious Diseases Research; Infrastructure; Institutes; Institution; Insulin; Intellectual Property; International; Investments; Lead; Leadership; Legal; Legal patent; Licensing; Market Research; Marketing; Medical Device; Mentors; Mentorship; Outcome; Pacific Northwest; Pathway interactions; Pharmacologic Substance; Process; Protein Engineering; Public Health; Recombinant Proteins; Recombinants; Recording of previous events; Research; Research Institute; Research Personnel; Research Support; Resources; Schools; Scientist; Services; Somatotropin; Somatropin; Structure; System; Talents; Technology; Technology Transfer; Therapeutic; Training; Translational Research; Translations; United States; United States National Institutes of Health; Universities; Vaccines; Washington; Work; Yeasts; base; burden of illness; clinical development; commercialization; design; disability; global health; health economics; health organization; improved; innovation; next generation; polypeptide; product development; professor; programs; success; translational health science

The University of Washington and the entrepreneurial community seeks to partner with the National Institutes of Health to become a Research Evaluation and Commercialization Hub (REACH) to accelerate academic biomedical discoveries into products helping ease the highest U.S. burden of disease and disability. The UW is a powerhouse in health sciences, technology, and innovation in a city known for seeking solutions to the most pressing health problems around the world. The University’s long-standing relationship with the entrepreneurial business community has helped in the formation of Boeing, Microsoft, Amazon, Immunex, Zymogenetics, Teblos, the Drug Interaction Database, and Seattle Genetics. It’s also led to well-recognized recombinant therapeutic and vaccine products such as growth hormone, insulin, RecombiVax HB®, and Gardasil®. Many of our graduates work at major health organizations in the city, including The Gates Foundation, Path, Fred Hutchinson Cancer Research Center, the Infectious Disease Research Institute. The University’s Foster School of Business gathers business leaders to judge and mentor solutions to health problems, and major business leaders are part of the governing board of these organizations and the networking hub The Washington Global Health Alliance and The Innovation Hub of Life Sciences Washington. In this rich spirt of collaboration, a hub to accelerate promising biomedical discoveries would fit right in. A hub is needed to further energize the spirit of discovery and collaboration and overcome barriers in getting products to the public. A hub will leverage existing resources for translational research and support the journey to fruition to innovative products that change lives. With institutional co-funding commitments, strong support of community leaders, and proven leadership in entrepreneurial startups, the four Aims of this proposal are to (1) Develop an integrated infrastructure and implementation system; (2) Identify the most promising technologies, and increase their availability using milestone-driven gap funding and mentoring (in business, marketing, and networking) for market-driven proof-of-product concept and product definition; (3) Fuel the formation of new biotechnology, pharmaceutical, and medical device companies, and assist in pathways to a self-sustaining structure; (4) Train the next generation of biomedical entrepreneurs to lead these ventures. With NIH support, this hub will accelerate the creation of small businesses using biomedical discoveries to launch products that impact health outcomes. An investment in the Pacific Northwest will amplify the returns on this funding due to the critical mass of investigators, and the will of our institutions to make this happen.

华盛顿大学和企业界寻求与美国国家研究院合作 成为一个研究评估和商业化中心（REACH），以加速学术 将生物医学发现转化为产品，帮助减轻美国最沉重的疾病和残疾负担。 华盛顿大学是一个以寻求解决方案而闻名的城市， 世界上最紧迫的健康问题。 大学与企业界的长期关系有助于 波音、微软、亚马逊、Immunex、Zymogenetics、Teblos、药物相互作用数据库的形成，以及 西雅图遗传学。它还导致了公认的重组治疗和疫苗产品，如生长 激素、胰岛素、RecombiVax HB®和Gardasil®。 我们的许多毕业生在城市的主要卫生组织工作，包括盖茨基金会，路径， 弗雷德哈钦森癌症研究中心，传染病研究所。大学的福斯特 商学院聚集商界领袖判断和导师的健康问题的解决方案，并主要 商业领袖是这些组织的管理委员会和网络中心的一部分。 华盛顿全球健康联盟和生命科学创新中心华盛顿。 在这种丰富的合作精神中，一个加速有前途的生物医学发现的中心将非常适合。集线器 需要进一步激发发现和合作的精神，并克服获得产品的障碍 向公众一个中心将利用现有资源进行转化研究，并支持以下旅程： 创新产品改变生活。在机构共同供资承诺的支持下， 社区领袖，并在创业初创公司的领导证明，这一建议的四个目标是（1） 开发一个综合的基础设施和实施系统;（2）确定最有前途的技术， 并利用里程碑驱动的缺口资金和指导（业务、营销和 网络），用于市场驱动的产品验证概念和产品定义;（3）推动新的 生物技术，制药和医疗设备公司，并协助途径，以自我维持 （4）培养下一代生物医学企业家领导这些企业。 在NIH的支持下，该中心将加速利用生物医学发现创建小企业， 推出影响健康结果的产品。在太平洋西北部的投资将扩大回报 由于调查人员的临界质量，以及我们机构实现这一目标的意愿，